1. Home
  2. AMWD vs CGEM Comparison

AMWD vs CGEM Comparison

Compare AMWD & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Woodmark Corporation

AMWD

American Woodmark Corporation

N/A

Current Price

$55.49

Market Cap

872.8M

ML Signal

N/A

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

N/A

Current Price

$14.09

Market Cap

780.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AMWD
CGEM
Founded
1980
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Forest Products
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
872.8M
780.4M
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
AMWD
CGEM
Price
$55.49
$14.09
Analyst Decision
Buy
Strong Buy
Analyst Count
2
10
Target Price
$66.00
$28.80
AVG Volume (30 Days)
149.1K
665.1K
Earning Date
01-01-0001
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.42
N/A
Revenue
$1,709,585,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.63
N/A
P/E Ratio
$38.72
N/A
Revenue Growth
N/A
N/A
52 Week Low
$47.15
$5.68
52 Week High
$72.95
$14.51

Technical Indicators

Market Signals
Indicator
AMWD
CGEM
Relative Strength Index (RSI) 39.60 66.84
Support Level $51.70 $11.43
Resistance Level $58.48 N/A
Average True Range (ATR) 2.92 0.94
MACD -1.08 0.17
Stochastic Oscillator 10.16 84.38

Price Performance

Historical Comparison
AMWD
CGEM

About AMWD American Woodmark Corporation

American Woodmark Corp manufactures and distributes cabinets and vanities for the remodeling and new home construction markets. It offers several products that fall into product lines including kitchen cabinetry, bath cabinetry, office cabinetry, home organization, and hardware. The products are sold under the brand names American Woodmark, Timberlake, Shenandoah Cabinetry, and Waypoint Living Spaces among others.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.

Share on Social Networks: